In part 2 (out next week), we discuss the placebo effect and results from a placebo controlled microdosing study from Balázs Szigeti Imperial College London. In part 3, we talk w/ the chief medical officers of MindMed Diamond Therapeutics about going for FDA approval for microdosing.

For those looking for more information about psychedelics and psychedelic therapy, check out the Berkeley Center’s new resources website, psychedelics.berkeley.edu

New episode: Microdosing (Part 3)! We discuss the path to FDA approval with... Dr. Dan Karlin: MindMed (LSD for adult ADHD) and Dr. Mike McDonnell: Diamond Therapeutics (psilocybin for anxiety disorders) Tune in here: businesstrip.fm/podcast/episod… mindmedco Diamond Therapeutics

Exciting news. Wishing all GEEKs much success!!

Diamond CEO Judy Blumstock discusses all things low-dose psilocybin with The Tonic. thetonic.ca/articles/healt…

Read the full release here: newswire.ca/news-releases/…

Excited to see our Phase 1 trial results and the potential for take-at-home psychedelic-derived drugs covered by Benzinga! benzinga.com/markets/cannab…

Diamond has received Health Canada approval to begin a Phase 2 clinical trial evaluating the safety, tolerability and efficacy of repeat low doses of psilocybin for the treatment of generalized anxiety disorder (GAD). lnkd.in/g3KpXHQU

Diamond’s Phase 2 trial has been approved by Health Canada, a Phase 2 randomized, double-blind study in adult patients with Generalized Anxiety Disorder. Patients will receive repeat low doses of psilocybin administered on a take-home basis. Diamond Therapeutics bit.ly/4048ppA

Today is #BellLetsTalk Day! One of the ways we can all take action is to learn about mental health organizations creating positive change for mental health in Canada…every day.

“Anxiety is the most common psychiatric disorder,” says Judy Blumstock, Diamond’s chief executive. “And the existing treatments aren’t satisfactory.” thestar.com/business/mars/…

Diamond is excited to announce our FDA-authorized clinical trial of low-dose psilocybin in collaboration with the University of Alabama at Birmingham. newswire.ca/news-releases/…

UAB and Diamond Therapeutics have announced a collaboration, researching low doses of psilocybin to treat demoralization. UAB School of Public Health professor Peter Hendricks, PhD is principle investigator in this five-week randomized clinical trial. Read more at go.uab.edu/40lKYXZ

Diamond is pleased to announce a strategic investment round led by First Avenue Ventures Life Science Fund I. newswire.ca/news-releases/…